Moreover, abnormal activation of FOXM1 also contributes to drug resistance in cancers, including ovarian cancer, breast cancer, prostate cancer, nasopharyngeal carcinoma, acute myeloid leukemia, and colorectal cancer [67,68,69,70,71,72]. This evidence concerns the gene FOXM1 and cancer.